Congenital Heart Disease, Covid-19
Conditions
Keywords
Congenital heart disease, Covid-19, Adults, Peadiarics
Brief summary
The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (\> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer. The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients. CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today. The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population. This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
Interventions
None listed
Sponsors
Pr. Jean-Benoît THAMBO, Bordeaux (président)
Dr. Céline GRUNENWALD GRONIER, Strasbourg
Dr. Sébastien HASCOET, Le Plessis-Robinson
Dr. Adeline BASQUIN, Rennes
Dr. Nicolas COMBES, Toulouse
Dr. Xavier IRIART, Bordeaux
Dr. Daniela LAUX, Paris
Dr. Magalie LADOUCEUR, Paris
Pr. BERTRAND LEOBON, Toulouse
Pr. Caroline OVAERT, Marseille
Dr. Karine WARIN-FRESSE, Nantes
Alexis BLANC, Montpellier
Pr. Roland HENAINE, Lyon
Hamouda ABASSI, Montpellier
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patient with CHD as defined in the international classification ACC-CHD * Covid-19 infection over the study period
Exclusion criteria
\- Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Covid-19 infection in the overall CHD population | through study completion, an average of 2 weeks | Prevalence of Covid-19 infection in the overall CHD population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Covid-19 infection per CHD sub-group | through study completion, an average of 2 weeks | Prevalence of Covid-19 infection per CHD sub-group |
| Cardiovascular complications | through study completion, an average of 2 weeks | Cardiovascular complications |
| Other complications | through study completion, an average of 2 weeks | Other complications |
| Number of deaths | through study completion, an average of 2 weeks | Number of deaths |
Countries
France
Outcome results
None listed